EULAR 2026：Dapirolizumab Pegol在系统性红斑狼疮中显示出降低复发率和维持疾病控制的潜力-动脉网

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

优时比等信源发布 2026-06-04 13:05



可切换为仅中文







BRUSSELS, Belgium and CAMBRIDGE, Mass. — June 4, 2026, 07:00 (CEST)

比利时布鲁塞尔和美国马萨诸塞州剑桥 — 2026年6月4日，07:00（中欧夏令时）

— UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE). .

— UCB（泛欧交易所布鲁塞尔：UCB）与渤健公司（纳斯达克：BIIB）今日在2026年欧洲风湿病联盟（EULAR）大会上公布了包括两张海报和三项摘要在内的数据，展示了在研生物制剂达匹罗珠单抗聚乙二醇（DZP）在系统性红斑狼疮（SLE）患者中的临床特征。

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs, including skin, joints and kidneys, often requiring long-term treatment to control disease activity.

系统性红斑狼疮（SLE）是一种影响皮肤、关节和肾脏等多个器官的慢性自身免疫性疾病，通常需要长期治疗以控制疾病活动。

Patients with SLE frequently experience flares, transient worsening of disease activity that can lead to permanent organ damage, increased morbidity, and even early mortality.

系统性红斑狼疮（SLE）患者常经历病情 flare，即疾病活动度的暂时性加重，可能导致永久性器官损伤、发病率增加，甚至早逝。

Many patients rely on steroid-based therapy to manage flares; however, prolonged steroid use is associated with significant cumulative toxicity, making steroid tapering while maintaining disease control a key goal in SLE management.

许多患者依赖类固醇治疗来控制病情发作；然而，长期使用类固醇与显著的累积毒性相关，因此在维持疾病控制的同时逐步减少类固醇用量成为系统性红斑狼疮（SLE）管理的关键目标。

3,4

“Achieving and maintaining durable disease control while reducing glucocorticoid exposure is one of the central challenges in managing SLE,” said Megan E. B. Clowse, M.D., MPH, Chief of the Division of Rheumatology and Immunology, Duke University, and primary author of the PHOENYCS GO primary results.

“在减少糖皮质激素暴露的同时实现并维持持久的疾病控制，是系统性红斑狼疮（SLE）管理中的核心挑战之一，”杜克大学风湿免疫科主任、PHOENYCS GO主要结果的第一作者Megan E. B. Clowse医学博士、公共卫生硕士表示。

“The Phase 3 PHOENYCS GO data showed patients receiving dapirolizumab pegol were more likely to maintain disease control while tapering steroids – an important finding given strong evidence that cumulative steroid exposure and uncontrolled disease activity are major drivers of organ damage accrual, morbidity and mortality in SLE.”.

“III期PHOENYCS GO研究数据显示，接受培戈达匹罗珠单抗治疗的患者在逐步减少糖皮质激素用量的同时更有可能维持疾病控制——鉴于有充分证据表明，累积的糖皮质激素暴露和未控制的疾病活动性是系统性红斑狼疮（SLE）患者器官损伤累积、 morbidity 和死亡率的主要驱动因素，这一发现具有重要意义。”

Post hoc analyses displayed in one of the posters from the PHOENYCS GO program showed that, in patients with baseline glucocorticoid dose >7.5 mg/day prednisone equivalent, treatment with DZP plus standard of care was associated with a higher proportion of patients achieving control of disease activity while enabling glucocorticoid tapering to ≤7.5 mg/day through Week 48, compared with placebo plus standard of care..

PHOENYCS GO 项目的一张海报中展示的事后分析显示，在基线糖皮质激素剂量大于每日 7.5 mg 泼尼松等效剂量的患者中，与安慰剂联合标准治疗相比，DZP 联合标准治疗可使更多患者实现疾病活动控制，并在第 48 周前将糖皮质激素减量至 ≤7.5 mg/天。

Importantly, these findings suggest that higher proportions of patients receiving DZP plus standard of care versus placebo plus standard of care achieved sustained glucocorticoid tapering while also achieving BICLA response, achieving SRI-4 response, or remaining free from moderate or severe BILAG-2004 flares through Week 48..

重要的是，这些研究结果表明，与接受安慰剂加标准治疗的患者相比，接受地西泮（DZP）加标准治疗的患者中有更高比例者在第48周时实现了持续的糖皮质激素减量，同时达到了BICLA反应、SRI-4反应，或无中度或重度BILAG-2004复发。

“At UCB, our mission is to help improve the lives of people living with serious inflammatory diseases by advancing therapies that address unmet needs,” said Donatello Crocetta, Chief Medical Officer and Head of Global Medical Affairs at UCB. “These data showed the potential of dapirolizumab pegol to reduce long-term glucocorticoid use while maintaining disease control, an important goal for people living with SLE and the clinicians who care for them.”.

“在UCB，我们的使命是通过推进满足未竟医疗需求的治疗方案，帮助改善严重炎症性疾病患者的生活，”UCB首席医学官兼全球医学事务负责人Donatello Crocetta表示。“这些数据展示了dapirolizumab pegol在维持疾病控制的同时减少长期糖皮质激素使用的潜力，这对于系统性红斑狼疮（SLE）患者及其临床医生而言是一个重要的目标。”

Additional EULAR 2026 presentations highlighted the breadth of data from the PHOENYCS GO program, including:

EULAR 2026 会议上的其他报告突显了 PHOENYCS GO 项目数据的广泛性，包括：

Improvements in key immunological markers, including reduced anti-dsDNA antibodies and increased complement proteins C3 and C4 in patients with abnormal levels at baseline (Poster POS1364).

关键免疫学指标的改善，包括基线水平异常的患者中抗双链DNA抗体减少以及补体蛋白C3和C4升高（海报POS1364）。

Lower rates of moderate or moderate/severe BILAG-2004 flares with DZP plus standard of care versus placebo plus standard of care through Week 48, using alternative definitions of flares to increase measurement sensitivity (Abstract AB1163).

至第48周，与安慰剂联合标准治疗相比，DZP联合标准治疗在采用替代性复发定义以提高测量敏感性的情况下，中度或中重度BILAG-2004复发率更低（摘要AB1163）。

Insights into how symptoms and flares are assessed in SLE, including fatigue as a burdensome patient-reported symptom that can be difficult to capture in clinical trials (Abstracts AB1184 and AB1125).

对系统性红斑狼疮（SLE）中症状和病情发作评估方式的见解，包括疲劳作为一种令患者负担沉重的主观报告症状，在临床试验中可能难以准确捕捉（摘要 AB1184 和 AB1125）。

8,9

Together, these findings support the importance of tools that can measure patient experience and help inform more meaningful assessment of disease impact in both clinical practice and research.

总之，这些发现支持了以下观点：能够衡量患者体验的工具至关重要，有助于在临床实践和研究中提供信息，从而对疾病影响进行更有意义的评估。

8,9

“Systemic lupus erythematosus is a biologically complex disease, and these EULAR data further characterize dapirolizumab pegol’s impact across clinical, biological and patient-reported outcomes,” said Diana Gallagher, MD, Head of Immunology, MS and Alzheimer’s Development Units at Biogen. “Delivering this data reflects the strength of the UCB and Biogen collaboration and our shared commitment to advancing evidence that may help address the complex and multifaceted needs of people living with SLE.” .

“系统性红斑狼疮是一种生物学上复杂的疾病，这些欧洲抗风湿病联盟（EULAR）的数据进一步表征了达匹罗珠单抗聚乙二醇（dapirolizumab pegol）在临床、生物学和患者报告结局方面的影响。”渤健（Biogen）免疫学、多发性硬化症和阿尔茨海默病研发部门主管 Diana Gallagher 医学博士表示。“发布这些数据体现了优时比（UCB）与渤健合作的实力，以及我们共同致力于推进证据开发，以帮助满足系统性红斑狼疮患者复杂且多方面的需求。”

The EULAR data follow the recent publication of the Phase 3 PHOENYCS GO study in The Lancet, reporting clinically meaningful improvements in disease activity with dapirolizumab pegol at Week 48.

继《柳叶刀》近期发表III期PHOENYCS GO研究结果之后，EULAR数据也相继公布，该研究报告显示，在第48周时，聚乙二醇化达匹罗珠单抗（dapirolizumab pegol）可使疾病活动度产生具有临床意义的改善。

In the Phase 3 PHOENYCS GO study, DZP demonstrated a generally favorable safety profile, with safety findings consistent with previous DZP studies.

在3期PHOENYCS GO研究中，DZP表现出总体良好的安全性特征，其安全性结果与此前DZP研究的结果一致。

10,11

Treatment-emergent adverse events were more common with DZP plus standard of care versus placebo plus standard of care, while serious treatment-emergent adverse events were less frequent in the DZP plus standard of care arm, and discontinuations due to treatment-emergent adverse events were low in both groups..

与安慰剂联合标准治疗相比，地西泮（DZP）联合标准治疗的治疗期不良事件更为常见，而地西泮联合标准治疗组的严重治疗期不良事件发生率较低，且两组因治疗期不良事件导致的停药率均较低。

十

About Dapirolizumab Pegol

关于达匹罗珠单抗聚乙二醇

Dapirolizumab pegol is a novel investigational humanized Fc-free polyethylene glycol (PEG)-conjugated antigen-binding (Fab’) fragment.

达匹珠单抗聚乙二醇是一种新型在研的人源化无Fc段聚乙二醇（PEG）偶联抗原结合（Fab’）片段。

十一

Dapirolizumab pegol inhibits CD40L signaling, which has been shown to reduce B-cell activation and autoantibody production, mitigate type 1 interferon (IFN) secretion and attenuate T-cell and antigen-presenting cell (APC) activation.

Dapirolizumab pegol 抑制 CD40L 信号传导，已证明其可减少 B 细胞活化和自身抗体产生，减轻 I 型干扰素（IFN）分泌，并减弱 T 细胞和抗原呈递细胞（APC）的活化。

十一

Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen.

达匹罗珠单抗聚乙二醇（Dapirolizumab pegol）目前正处于治疗系统性红斑狼疮（SLE）的III期临床开发阶段，该开发项目由优时比（UCB）与渤健（Biogen）合作开展。

12,13

Dapirolizumab pegol is an investigational biologic currently in clinical development. The safety and efficacy have not been established, and it is not approved by any health authority worldwide.

达匹罗珠单抗聚乙二醇是一种处于临床研究阶段的在研生物制品。其安全性和有效性尚未确立，且未获得全球任何卫生监管机构的批准。

About UCB

关于 UCB

UCB, Brussels, Belgium (www.ucb.com), is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025.

优时比（UCB），总部位于比利时布鲁塞尔（www.ucb.com），是一家全球性生物制药公司，专注于发现和开发创新药物及解决方案，以改善患有严重免疫系统或中枢神经系统疾病患者的生活。公司在约40个国家拥有约9,000名员工，2025年实现营业收入77亿欧元。

UCB is listed on Euronext Brussels (symbol: UCB)..

UCB 在布鲁塞尔泛欧交易所上市（股票代码：UCB）。

About Biogen

关于渤健

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.

渤健成立于1978年，是一家领先的生物技术公司，通过开拓创新科学，提供新药以改变患者生活，并为股东和社区创造价值。我们运用对人类生物学的深刻理解，并利用不同技术平台，推进首创疗法或治疗方案，以实现更优的治疗效果。

Our approach is to take bold risks, balanced with return on investment to deliver long-term growth..

我们的策略是大胆承担风险，同时兼顾投资回报，以实现长期增长。

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

我们经常在我们的网站www.biogen.com上发布可能对投资者重要的信息。在社交媒体上关注我们 - Facebook、LinkedIn、X、YouTube。

Forward-looking Statements - UCB

前瞻性陈述 - UCB

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述，包括但不限于含有“潜在”、“相信”、“预期”、“期望”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”及类似表述的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

除历史事实陈述外，所有陈述均可能被视为前瞻性陈述，包括对收入、营业利润率、资本支出、现金及其他财务信息的估计，以及对法律、仲裁、政治、监管或临床试验结果或实践的预期，以及其他此类估计和结果。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document. .

就其性质而言，此类前瞻性陈述并不保证未来表现，且受已知和未知的风险、不确定性及假设的影响，这些因素可能导致优时比（UCB）的实际业绩、财务状况、表现或成就，或行业结果，与本文件中所载前瞻性陈述所明示或暗示的任何未来结果、表现或成就存在重大差异。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees.

可能导致此类差异的重要因素包括但不限于：战争、流行病和恐怖主义的全球蔓延及其影响；总体地缘政治环境；气候变化；总体经济、商业和竞争状况的变化；无法获得必要的监管批准，或无法以可接受的条款或在预期的时间内获得此类批准；与研发相关的成本；优时比（UCB）管线中或正在开发的产品前景变化；未来司法判决或政府调查的影响；安全、质量、数据完整性或生产问题；供应链中断和业务连续性风险；潜在或实际的数据安全和数据隐私泄露，或优时比信息技术系统的中断；产品责任索赔；对产品或候选产品的专利保护提出的挑战；来自其他产品（包括生物类似药）或颠覆性技术/商业模式竞争；法律或法规的变化；汇率波动；与税收和关税相关的法律和/或规则或其执行方面的变化或不确定性；以及员工的招聘、留任和合规问题。

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans.

无法保证在研发管线中发现或确定新的候选产品，也无法保证现有产品的新适应症会得到开发和批准。从概念到商业化产品的过程存在不确定性；临床前研究结果并不能保证候选产品在人体中的安全性和有效性。

So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has.

迄今为止，人体的复杂性尚无法在计算机模型、细胞培养系统或动物模型中重现。完成临床试验并获得产品上市监管批准所需的时间长度也是如此。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于存在上述不确定性，提醒公众不要过度依赖此类前瞻性陈述。这些前瞻性陈述仅反映截至本文件发布之日的情况，并未体现上述不断演变的事件或风险以及其他不利因素可能产生的任何潜在影响，除非另有说明。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

公司继续密切关注事态发展，以评估这些事件对UCB的财务影响（如适用）。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations..

优时比（UCB）明确声明，除非适用法律和法规另有要求，否则其无任何义务更新本文件中的任何前瞻性陈述，无论是为了确认实际结果，还是为了报告或反映其前瞻性陈述的任何变化，或反映此类陈述所依据的事件、条件或情况的任何变化。

Biogen Safe Harbor

渤健安全港声明

This news release contains forward-looking statements, including, among others, relating to: the potential benefits, safety and efficacy of dapirolizumab pegol (DZP); the potential of dapirolizumab pegol to address the needs of people living with systemic lupus erythematosus (SLE), including the potential to help patients maintain disease control while tapering steroids; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with UCB; the potential of Biogen's commercial business and pipeline programs, including dapirolizumab pegol; potential regulatory discussions, submissions and approvals and the timing thereof; and the risks and uncertainties associated with drug development and commercialization.

本新闻稿包含前瞻性陈述，包括但不限于以下内容：达匹罗珠单抗聚乙二醇（DZP）的潜在益处、安全性和有效性；达匹罗珠单抗聚乙二醇满足系统性红斑狼疮（SLE）患者需求的潜力，包括帮助患者在逐步减少类固醇用量的同时维持疾病控制的潜力；Biogen与UCB合作安排的预期益处、风险和潜力；Biogen商业业务和管线项目（包括达匹罗珠单抗聚乙二醇）的潜力；潜在的监管讨论、提交和批准及其时间安排；以及与药物开发和商业化相关的风险和不确定性。

These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning.

这些前瞻性陈述可能伴随使用“旨在”、“预期”、“假设”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“预测”、“目标”、“指引”、“希望”、“打算”、“可以”、“目的”、“展望”、“计划”、“可能的”、“潜在的”、“预言”、“规划”、“前景”、“应当”、“指标”、“将”、“将会”等词语以及具有类似含义的其他词汇和术语。

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

药物开发和商业化涉及高度风险，只有少数研发项目最终实现产品的商业化。早期临床试验的结果可能无法反映完整结果或后期及更大规模临床试验的结果，也不能确保获得监管批准。

You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. .

您不应过度依赖这些陈述。鉴于其前瞻性性质，这些陈述涉及重大的风险和不确定性，可能基于不准确的假设，并可能导致实际结果与这些陈述中反映的结果存在重大差异。

These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to: uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our relia.

这些前瞻性陈述基于管理层当前的信念和假设，以及管理层目前可获得的信息。鉴于其性质，我们无法保证这些前瞻性陈述中表达的任何结果会全部或部分实现。我们提醒，这些陈述受风险和不确定性的影响，其中许多不在我们的控制范围内，并可能导致未来事件或结果与本文件中陈述或暗示的内容存在重大差异，包括但不限于以下因素：我们在开发、许可或收购其他候选产品或现有产品的额外适应症方面长期成功的不确定性；与产品批准、现有产品额外适应症的批准、销售、定价、增长、报销以及已上市产品和在研产品的推出相关的行动的预期、计划、前景和时间安排；生物制药和医疗保健行业以及我们参与竞争的任何其他市场中产品竞争加剧的潜在影响，包括来自新原研疗法、仿制药、前药和现有产品的生物类似药以及通过简化监管途径批准的产品的竞争加剧；我们有效实施公司战略的能力；在获得和维持我们产品的充分覆盖、定价和报销方面存在的困难；推动我们业务增长的因素，包括我们在产品开发、监管批准和商业化以及业务其他方面对合作者和其他第三方的依赖，这些因素不完全在我们的控制范围内；与生物类似药商业化相关的风险，此类风险涉及我们的可靠性。

These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected.

这些陈述仅反映本演示文稿及本次电话会议讨论之日的情况，并基于我们目前可获得的信息和估计。如果已知或未知的风险或不确定性成为现实，或者基本假设被证明不准确，实际结果可能与过往结果以及预期、估计或预测的结果存在重大差异。

Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise..

投资者被提醒不要过度依赖前瞻性陈述。有关风险、不确定性和其他事项的进一步列表和描述，可在我们截至2025年12月31日财政年度的10-K表格年度报告以及后续的10-Q表格报告中找到。除非法律要求，我们没有义务因任何新信息、未来事件、情况变化或其他原因而公开更新任何前瞻性陈述。

Biogen Digital Media Disclosure

渤健数字媒体披露

From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD).

我们不时使用或预计未来将使用我们的投资者关系网站（investors.biogen.com）、Biogen 的 LinkedIn 账户（linkedin.com/company/biogen-）以及 Biogen 的 X 账户（https://x.com/biogen），作为以广泛、非排他性的方式向公众披露信息的手段，包括用于满足美国证券交易委员会《公平披露条例》（Reg FD）的目的。

Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors..

因此，投资者除了关注我们的新闻稿、美国证券交易委员会（SEC）文件、公开电话会议和网站外，还应监控我们的投资者关系网站及这些社交媒体渠道，因为发布在这些平台上的信息可能对投资者具有重大影响。

References:

参考文献：

Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-68.

Pons-Estel GJ，Alarcón GS，Scofield L，等. 系统性红斑狼疮的流行病学与进展. 《关节炎与风湿病研讨会》. 2010;39(4):257-68.

Thanou A, Jupe E, Purushothaman M, et al. Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun. 2021;119:102615. doi:10.1016/j.jaut.2021.102615.

Thanou A, Jupe E, Purushothaman M, 等. 系统性红斑狼疮的临床疾病活动度与复发：当前概念与新型生物标志物. 《自身免疫杂志》. 2021;119:102615. doi:10.1016/j.jaut.2021.102615.

Palmowski A, Pankow A, Terziyska K, et al. Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2024;64:152349.

Palmowski A, Pankow A, Terziyska K, 等. 在低疾病活动度或缓解期的类风湿关节炎和系统性红斑狼疮患者中，持续使用与逐渐减量低剂量糖皮质激素的对比：随机试验的系统评价和荟萃分析. 《Seminars in Arthritis and Rheumatism》. 2024;64:152349.

doi:10.1016/j.semarthrit.2023.152349..

doi:10.1016/j.semarthrit.2023.152349

Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45. doi:10.1136/annrheumdis-2019-215089.

Fanouriakis A, Kostopoulou M, Alunno A, 等. 2019年欧洲抗风湿病联盟（EULAR）系统性红斑狼疮管理建议更新. 《风湿病年鉴》. 2019;78(6):736–45. doi:10.1136/annrheumdis-2019-215089.

Morand EF, Bertsias G, Carter LM, et al. Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48 week results from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):POS0730.

Morand EF，Bertsias G，Carter LM，等。系统性红斑狼疮患者减少糖皮质激素使用的疾病控制维持治疗：达匹珠单抗聚乙二醇化制剂III期临床试验的48周结果。《风湿病年鉴》. 2026;85(增刊1):POS0730.

Dörner T, Pisetsky DS, Fava A, et al. Dapirolizumab pegol treatment and improvement in laboratory markers of disease activity in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial. Ann Rheum Dis. 2026;85(Suppl 1):POS1364.

Dörner T, Pisetsky DS, Fava A, 等. Dapirolizumab pegol治疗及系统性红斑狼疮患者疾病活动度实验室指标的改善：一项3期试验的48周结果. 《风湿病年鉴》. 2026;85(增刊1):POS1364.

Furie RA, Bertsias G, Carter LM, et al. Dapirolizumab pegol and flare reduction in patients with systemic lupus erythematosus in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice. Ann Rheum Dis. 2026;85(Suppl 1):AB1163.

Furie RA, Bertsias G, Carter LM, 等. Dapirolizumab pegol 在系统性红斑狼疮患者中减少疾病复发的48周3期临床试验：对反映临床实践的替代复发定义的更新事后分析. 《风湿病年鉴》. 2026;85(增刊1):AB1163.

de la Loge C, Touma Z, Gordon C, et al. Measuring fatigue in systemic lupus erythematosus: measurement properties of the FATIGUE-PRO total score using data from a phase 3 trial of dapirolizumab pegol. Ann Rheum Dis. 2026;85(Suppl 1):AB1184.

de la Loge C，Touma Z，Gordon C，等。测量系统性红斑狼疮的疲劳：使用达匹罗珠单抗聚乙二醇（dapirolizumab pegol）III期临床试验数据评估FATIGUE-PRO总分的测量特性。《风湿病年鉴》. 2026;85(增刊1):AB1184.

Mosca M, Anjohrin S, Rawlings A, et al. Physicians’ perspectives on recognition of flares in patients with systemic lupus erythematosus in the clinic: real world insights from the United States and Europe. Ann Rheum Dis. 2026;85(Suppl 1):AB1125.

Mosca M, Anjohrin S, Rawlings A, 等. 临床医生对系统性红斑狼疮患者病情发作识别的看法：来自美国和欧洲的真实世界见解. 《风湿病年鉴》. 2026;85(增刊1):AB1125.

Clowse MEB, Isenberg DA, Merrill JT, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Published online May 29, 2026. doi:10.1016/S0140-6736(26)00691-4.

Clowse MEB，Isenberg DA，Merrill JT，等。CD40配体抑制剂dapirolizumab pegol在系统性红斑狼疮中的疗效和安全性（PHOENYCS GO）：一项随机、双盲、安慰剂对照的3期临床试验。《柳叶刀》。2026年5月29日在线发表。doi:10.1016/S0140-6736(26)00691-4。

Furie RA, Bruce IN, Dörner T, et al. Phase 2 randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate to severe active systemic lupus erythematosus (SLE). Rheumatology (Oxford). 2021;60(11): 5397-407.

Furie RA, Bruce IN, Dörner T, 等. 聚乙二醇化达匹珠单抗治疗中度至重度活动性系统性红斑狼疮（SLE）患者的II期随机、安慰剂对照试验. 《风湿病学》（牛津）. 2021;60(11): 5397-407.

ClinicalTrials.gov. NCT04294667.

ClinicalTrials.gov. NCT04294667。

https://clinicaltrials.gov/study/NCT04294667

. Accessed May 29, 2026.

访问日期：2026年5月29日。

ClinicalTrials.gov. NCT06617325.

ClinicalTrials.gov. NCT06617325。

https://clinicaltrials.gov/study/NCT06617325

. Accessed May 29, 2026.

访问于2026年5月29日。

###